ACHC · Acadia Healthcare Company, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.31B | $3.15B | $2.93B | $2.61B | $2.31B | $2.09B |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - |
| SG&A | $177.60M | $156.80M | $153.30M | $124.30M | $108.20M | $97.80M |
| Total Operating Expenses | $4.38B | $2.81B | $2.95B | $2.24B | $2.04B | $1.91B |
| D&A | $189.25M | $149.59M | $132.35M | $117.77M | $106.72M | $95.26M |
| Operating Income | ($1.07B) | $341.88M | ($25.36M) | $374.14M | $275.76M | $183.80M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $25.98M | $77.39M | ($9.70M) | $94.11M | $67.56M | $40.61M |
| Net Income | ($1.10B) | $255.61M | ($21.67M) | $273.14M | $190.63M | ($672.13M) |
| EPS - Basic | ($12.16) | $2.79 | ($0.24) | $3.05 | $2.15 | ($7.65) |
| EPS - Diluted | ($12.16) | $2.78 | ($0.24) | $2.98 | $2.10 | ($7.59) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $133.24M | $76.31M | $100.07M | $97.65M | $133.81M | $378.70M |
| Accounts Receivable | $440.60M | $365.34M | $361.45M | $322.44M | $281.33M | $273.55M |
| Inventory | $5.69M | $5.65M | $5.30M | $5.09M | $4.79M | $4.85M |
| Accounts Payable | $150.40M | $232.70M | $156.13M | $104.72M | $98.58M | $87.81M |
| Current Assets | $814.14M | $577.49M | $596.00M | $506.13M | $495.03M | $2.52B |
| Total Assets | $5.53B | $5.96B | $5.36B | $4.99B | $4.77B | $6.50B |
| Current Liabilities | $525.19M | $577.92M | $885.78M | $388.33M | $404.86M | $1.31B |
| Long-term Debt | $2.47B | $1.88B | $1.34B | $1.36B | $1.48B | $2.97B |
| Total Liabilities | $3.39B | $2.77B | $2.47B | $2.09B | $2.19B | $4.54B |
| Stockholders' Equity | $1.95B | $3.07B | $2.78B | $2.81B | $2.52B | $1.90B |
| Retained Earnings | ($765.84M) | $387.33M | $131.72M | $153.39M | ($119.75M) | ($310.39M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $131.90M | $129.69M | $462.34M | $380.57M | $374.48M | $658.81M |
| Investing Cash Flow | ($556.21M) | ($736.48M) | ($397.22M) | ($305.83M) | $1.02B | ($281.84M) |
| Financing Cash Flow | $481.25M | $583.02M | ($62.70M) | ($110.90M) | ($1.64B) | ($51.50M) |
| CapEx | $571.81M | $690.38M | $424.13M | $296.15M | $244.81M | $216.62M |
| Free Cash Flow | ($439.91M) | ($560.69M) | $38.21M | $84.42M | $129.67M | $442.19M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | -32.2% | 10.8% | -0.9% | 14.3% | 11.9% | 8.8% |
| EBITDA margin | -26.5% | 15.6% | 3.7% | 18.8% | 16.5% | 13.4% |
| Net margin | -33.3% | 8.1% | -0.7% | 10.5% | 8.2% | -32.2% |
| Free cash flow margin | -13.3% | -17.8% | 1.3% | 3.2% | 5.6% | 21.2% |
| FCF / Net income | 0.40 | -2.19 | -1.76 | 0.31 | 0.68 | -0.66 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | 5.4% | 5.0% | 5.2% | 4.8% | 4.7% | 4.7% |
| Effective tax rate | - | 23.2% | - | 25.6% | 26.2% | - |
| Return on assets | -20.0% | 4.3% | -0.4% | 5.5% | 4.0% | -10.3% |
| Return on equity | -56.6% | 8.3% | -0.8% | 9.7% | 7.6% | -35.4% |
| Return on invested capital | -19.0% | 5.3% | -0.5% | 6.7% | 5.1% | 3.0% |
| Liquidity | ||||||
| Current ratio | 1.55 | 1.00 | 0.67 | 1.30 | 1.22 | 1.93 |
| Quick ratio | 1.54 | 0.99 | 0.67 | 1.29 | 1.21 | 1.93 |
| Cash ratio | 0.25 | 0.13 | 0.11 | 0.25 | 0.33 | 0.29 |
| Leverage | ||||||
| Debt / Equity | 1.27 | 0.61 | 0.48 | 0.49 | 0.59 | 1.56 |
| Debt / Assets | 0.45 | 0.32 | 0.25 | 0.27 | 0.31 | 0.46 |
| Debt / EBITDA | - | 3.83 | 12.55 | 2.77 | 3.87 | 10.64 |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 2.84 | 1.94 | 1.93 | 1.77 | 1.89 | 3.42 |
| Liabilities / Assets | 0.61 | 0.46 | 0.46 | 0.42 | 0.46 | 0.70 |
| Efficiency | ||||||
| Asset turnover | 0.60 | 0.53 | 0.55 | 0.52 | 0.49 | 0.32 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 49d | 42d | 45d | 45d | 44d | 48d |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | 14.3x | - | 27.6x | 28.9x | - |
| P / B | 0.7x | 1.2x | 2.5x | 2.7x | 2.2x | 2.3x |
| P / S | 0.4x | 1.2x | 2.4x | 2.9x | 2.4x | 2.1x |
| EV / EBITDA | - | 11.1x | 77.7x | 17.9x | 17.9x | 25.2x |
| Growth | ||||||
| Revenue growth (YoY) | 5.0% | 7.7% | 12.2% | 12.8% | 10.7% | -32.7% |
| Revenue CAGR (3y) | 8.3% | 10.9% | 11.9% | -5.6% | -6.3% | - |
| Revenue CAGR (5y) | 9.7% | 0.3% | 0.8% | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | 35.7% | 50.0% | -68.6% |
| Net income growth (YoY) | - | - | - | 43.3% | - | - |
| EPS growth (YoY) | - | - | - | 41.9% | - | - |
| EPS CAGR (3y) | - | 9.8% | - | 33.9% | - | - |
| EPS CAGR (5y) | - | 17.5% | - | 5.3% | 97.4% | - |
| FCF growth (YoY) | 21.5% | - | -54.7% | -34.9% | -70.7% | 817.0% |
| FCF CAGR (5y) | - | - | -12.1% | -7.6% | 19.1% | - |
| Book value growth (YoY) | -36.6% | 10.5% | -1.1% | 11.7% | 32.5% | -24.2% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$3.31B totalUnited States Facilities$3.31B · 100.0%
Product / service
$3.31B totalAcute Inpatient Psychiatric Facilities$1.83B · 55.3%
Specialty Treatment Facilities$567.20M · 17.1%
Comprehensive Treatment Centers$567.18M · 17.1%
Residential Treatment Centers$348.07M · 10.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.16
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Services-Specialty Outpatient Facilities, NEC
Comparing Acadia Healthcare Company against the 5 most active filers in the same SIC group.